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Abstract
Background: The presence of EGFR kinase domain mutations in a subset of NSCLC patients
correlates with the response to treatment with the EGFR tyrosine kinase inhibitors gefitinib and
erlotinib. Although most EGFR mutations detected are short deletions in exon 19 or the L858R
point mutation in exon 21, more than 75 different EGFR kinase domain residues have been
reported to be altered in NSCLC patients. The phenotypical consequences of different EGFR
mutations may vary dramatically, but the majority of uncommon EGFR mutations have never been
functionally evaluated.
Results: We demonstrate that the relative kinase activity and erlotinib sensitivity of different EGFR
mutants can be readily evaluated using transfection of an YFP-tagged fragment of the EGFR
intracellular domain (YFP-EGFR-ICD), followed by immunofluorescence microscopy analysis. Using
this assay, we show that the exon 20 insertions Ins770SVD and Ins774HV confer increased kinase
activity, but no erlotinib sensitivity. We also show that, in contrast to the common L858R mutation,
the uncommon exon 21 point mutations P848L and A859T appear to behave like functionally silent
polymorphisms.
Conclusion: The ability to rapidly obtain functional information on EGFR variants of unknown
relevance using the YFP-EGFR-ICD assay might prove important in the future for the management
of NSCLC patients bearing uncommon EGFR mutations. In addition, our assay may be used to
determine the response of resistant EGFR mutants to novel second-generation TKIs.
Background
Approximately 80% of lung cancers, the most frequently
diagnosed type of human tumor, are classified as non-
small cell lung cancer (NSCLC). Novel therapeutic agents
for the treatment of NSCLC patients are currently under
intense experimental and clinical investigation, with the
goal of increasing their antitumor effect while reducing
general toxicity. These agents specifically target cellular
pathways necessary for the survival of cancer cells. The
epidermal growth factor receptor (EGFR) is a receptor
tyrosine kinase (TK) whose activation initiates signal
transduction through critical cellular pathways, such as
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tant role in controlling cell homeostasis [1]. EGFR is over-
expressed or aberrantly activated in different types of
human tumors, contributing to the malignant phenotype
of cancer cells, and targeted inactivation of EGFR is being
intensively explored as a cancer therapeutic approach [2].
As a result of these investigations, several small-molecule
EGFR tyrosine-kinase inhibitors (TKIs), such as gefitinib
and erlotinib, have been developed and are currently
available in the clinic. In large clinical studies of gefitinib
and erlotinib, it became apparent that a minor subset of
NSCLC patients is extremely sensitive to treatment with
EGFR-TKIs [reviewed in [3]]. Subsequently, the analysis of
EGFR gene sequence revealed the presence of somatic
mutations in the kinase domain of the receptor in most
responding patients [4-6]. The association between the
presence of EGFR mutations and response to TKIs has
been confirmed through the analysis of thousands of
NSCLC tumor samples worldwide. These results raise the
possibility that EGFR mutational analysis may be imple-
mented for the management of NSCLC patients [7].
Approximately 80% of the EGFR mutations detected are
short deletions in exon 19 affecting the amino acid
sequence ELREA (Del746-750), or a point mutation in
exon 21 resulting in the amino acid change L858R. How-
ever, the data accumulated in the past three years have
uncovered the large allelic heterogeneity that characterizes
EGFR kinase mutations. Thus, a survey of the COSMIC
mutation database [8] shows that more than 75 different
EGFR kinase domain residues have been reported to be
altered in NSCLC patients.
The functional characteristics of the two most common
types of EGFR alterations, the exon 19 deletions and the
L858R point mutation, have been studied in detail using
biochemical assays, cell-based systems and mouse models
[4-6], [9-14]. Additionally, a limited number of less com-
mon mutant alleles of EGFR have been tested using trans-
fection-based approaches [15-22]. Nevertheless, the
biological effect of most uncommon EGFR alterations has
never been evaluated. The phenotypical effect of the par-
ticular alteration detected in tumor cells may largely
account for the response of the patient to treatment. In
this regard, certain mutations, such as the T790M amino
acid change, have been shown to confer resistance to gefit-
inib and erlotinib [reviewed in [7]]. Second-generation
TKIs, which bind covalently to EGFR and may be active
against these resistant mutants, are currently being devel-
oped.
To allow for a more rapid characterization of untested
EGFR mutants, and to facilitate the testing of novel poten-
tial anti-EGFR agents, we aimed here to establish a simple
cellular assay to evaluate the effect of EGFR mutations and
the response of different EGFR variants to erlotinib. To
this end, we used site-directed mutagenesis to introduce
cancer-associated mutations into an YFP-tagged fragment
of EGFR intracellular domain (YFP-EGFR-ICD). These chi-
merical proteins were transiently expressed in human
cells, and the effect of their expression was assessed on a
single-cell basis using immunofluorescence with phos-
phorylation-specific antibodies.
We demonstrate here that the YFP-EGFR-ICD-based assay
can be used to evaluate the relative kinase activity and
erlotinib sensitivity of EGFR mutants, and we use this
approach to test several uncommon EGFR mutations.
Results
Increased autophosphorylation of YFP-tagged EGFR 
intracellular domain the common EGFR Del746 mutation
We generated an YFP-tagged fragment of EGFR (Figure
1A) encompassing residues 688–1116 (the numbering
system includes the 24 amino acid signal peptide of
EGFR). This fragment, termed YFP-EGFR-ICD, contains
the TK domain, as well as sequences from the adjacent reg-
ulatory motif, but lacks the extracellular and the juxtam-
embrane domains of the receptor. The Del746-750
mutation (hereafter called Del746) was next introduced
into YFP-EGFR-ICD using site-directed mutagenesis. This
mutant, representative of the common and well-charac-
terized exon 19 deletions, was used as a positive control in
the initial experiments to test the suitability of our system.
MCF-7 breast cancer cells were transfected with plasmids
encoding YFP-EGFR-ICD wt or YFP-EGFR-ICD Del746,
and examined using fluorescence microscopy. Approxi-
mately 30% of the cells expressing the mutant EGFR ICD
showed long lamellipodial protrusions, which were not
observed in cells expressing the wt fragment (Figure 1B).
Cells were fixed 24 hours after transfection and immunos-
tained using specific primary antibodies to detect phos-
phorylation of EGFR tyrosine residues Y869 and Y1092.
Using secondary antibodies conjugated to the red fluoro-
phore Alexa Fluor-594 (AF-594) and YFP positivity as a
marker of transfection, we were able to examine YFP-
EGFR-ICD phosphorylation in a single-cell basis (Figure
1C). Non-transfected MCF-7 cells did not contain detect-
able levels of phosphorylated EGFR. YFP-EGFR-ICD wt-
transfected cells showed no or barely detectable pY869 or
pY1092. In contrast, cells expressing comparable levels of
the mutant protein (as indicated by the intensity of the
YFP signal) showed a robust immunostaining signal for
both residues. The anti-pY1092 antibody provided the
clearest result, and was therefore used in subsequent anal-
yses. Similar experiments were carried out with a shorter
EGFR fragment containing only the TK domain (amino
acids 688–982), but no autophosphorylation (pY869)
was detected (data not shown).Page 2 of 10
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Common NSCLC-associated EGFR mutations lead to increased autophosphorylation of an YFP-tagged EGFR intracellular domainFigure 1
Common NSCLC-associated EGFR mutations lead to increased autophosphorylation of an YFP-tagged EGFR intracellular domain. A. 
Schematic representation of full-length EGFR and YFP-EGFR-ICD. The amino acid numbering includes the 24 residues of the signal peptide. YFP-EGFR-
ICD contains the tyrosine kinase (TK) domain and part of the regulatory region (Reg), but lacks the extracellular and juxtamembrane (JM) domains. B. 
Expression of YFP-EGFR-ICD Del746 induces morphological changes in MCF-7 cells. Unlike cells transfected with wild type (WT) YFP-EGFR-ICD, MCF-7 
cells expressing YFP-EGFR-ICD Del746 frequently show long lamellipodial protrusions (arrowheads). C Using immunofluorescence, increased autophos-
phorylation of YFP-EGFR-ICD Del746 at tyrosine residues Y869 (left set of panels) and Y1092 (right set of panels) can be detected. Phosphorylation is vir-
tually undetectable in cells expressing YFP-EGFR-ICD WT. Images were taken using 160 × magnification and the exposure time indicated inside the panels. 
The fluorescent signal was consistently brighter using the anti-pY1092 antibody (note the shorter exposure time used). D. Semi-quantitative comparison of 
YFP-EGFR-ICD autophosphorylation level using computer-assisted image analysis. Images of several transfected cells (400 × magnification) were taken 
using 40 ms (YFP) or 160 ms (AF-594) exposure times. The fluorescence intensity in the green and the red channels was measured within a cytoplasmic 
area (YFP signal and AF-594 signal), and within an area outside the cells (background). In the graph, the intensity of the YFP and AF-594 fluorophores for 
each cell was plotted against each other using Excel, and the best-fitting trend lines (highest R2) were added. At similar expression levels (YFP intensity), 
the level of pY1092 is higher for YFP-EGFR-ICD bearing the Del746 mutation (white squares) than for the wild type protein (circles). The V948R mutation 
(open triangles) virtually abrogated autophosphorylation. The experiment was repeated twice with similar results. Graph shows the data from one exper-
iment. au: arbitrary units.
Molecular Cancer 2007, 6:56 http://www.molecular-cancer.com/content/6/1/56We used computer-assisted image analysis to measure the
intensity of the YFP and AF-594 signals in the cytoplasm
of several individual cells (Figure 1D, left images). In
addition to wt and Del746, an YFP-EGFR-ICD protein
bearing the experimental V948R mutation was tested. This
amino acid change has been shown to maintain EGFR
kinase domain in an inactive conformation [23]. In line
with previous data, autophosphorylation was dramati-
cally increased by the Del746 mutation (Figure 1D,
graph). It should be pointed out that cells expressing very
high levels of the wt ICD showed weak but detectable
Y1092 phosphorylation. The V948R change, as expected,
virtually abrogated ICD autophosphorylation even at the
highest levels of expression.
Altogether, these results demonstrate that the effect of
NSCLC-related EGFR mutations on basal autophosphor-
ylation can be rapidly evaluated on a single cell basis
using transient transfection of YFP-EGFR-ICD and
immunofluorescence.
Evaluating erlotinib sensitivity of EGFR mutants in the con-text of YFP-EGFR-ICDFig re 3
Evaluating erlotinib sensitivity of EGFR mutants in 
the context of YFP-EGFR-ICD. A. Representative exam-
ples of MCF-7 cells expressing YFP-EGFR-ICD wild type, 
Del746 or Del746/T790M (green), stained for endogenous 
phosphorylated Akt (red). Cells were treated for 20 hours 
with the indicated concentration of erlotinib. The different 
response of each EGFR variant to erlotinib treatment is read-
ily visualized by immunoflourescence. YFP-EGFR-ICD wild 
type does not induce Akt phosphorylation, and relocates into 
thick cytoplasmic fibrils at 10 µM erlotinib. One thousand-
fold lower concentration of the drug (10 nM) inhibited 
Del746-induced Akt phosphorylation, and caused fibrilar 
relocation of the ectopic protein. The double mutant 
Del746/T790M did not form fibrils and induced Akt phos-
phorylation even in the presence of 10 µM erlotinib. B. 
Images show that YFP-EGFR-ICD Del746 (green) remains 
phosphorylated at Y1092 (red) after relocating into fibrils in 
the presence of erlotinib.
Activation of Akt and Erk pathways in cells expressing mutan  YFP-EGFR-ICD Del746Figure 2
Activation of Akt and Erk pathways in cells express-
ing mutant YFP-EGFR-ICD Del746. A. Panels show rep-
resentative images (400X) of MCF-7 cells expressing YFP-
EGFR-ICD wild type, Del746 or V948R, analyzed by immun-
ofluorescence to detect phosphorylated Akt (pAkt). Phos-
phorylation of endogenous Akt was only detected in cells 
expressing the Del746-bearing protein. B. A similar analysis 
was carried out to detect phosphorylated ERK (pERK). Only 
cells expressing YFP-EGFR-ICD Del746 contained detectable 
levels of endogenous pERK. Exposure time is indicated inside 
the panels. DNA was counterstained with Hoechst. C. 
Images (400X) illustrate two morphological characteristics of 
Akt phosphorylation in cells expressing YFP-EGFR-ICD 
Del746. On one hand, pAkt showed a preferential localiza-
tion to membrane ruffles, and often accumulated at the tip of 
lamellipodial protrusions (arrowhead). On the other hand, 
cells expressing high (cell#1) or low (cell#2) levels of YFP-
EGFR-ICD Del746, often contained similar levels of pAkt.Page 4 of 10
(page number not for citation purposes)
Molecular Cancer 2007, 6:56 http://www.molecular-cancer.com/content/6/1/56Activation of EGFR downstream signaling pathways in cells 
expressing mutant YFP-EGFR-ICD Del746
Signal transduction downstream of EGFR and, ultimately,
the cellular response to EGFR activation, relies on the inte-
grated activity of several intracellular signaling pathways,
such as those mediated by Akt or ERK. Phosphorylation of
ERK and Akt at specific residues, which constitutes a key
activating event in these pathways, is widely used as a
marker of active EGFR downstream signaling.
MCF-7 cells transfected with YFP-EGFR-ICD wt, Del746 or
V948R, were immunostained using specific antibodies to
detect endogenous phosphorylated Akt (pAkt-S473) and
phosphorylated ERK (pERK-T202/Y204). The levels of
pAkt (Figure 2A) and pERK (Figure 2B) were undetectable
in non transfected cells as well as in cells expressing YFP-
EGFR-ICD wt or YFP-EGFR-ICD V948R. In contrast, phos-
phorylation of both Akt and ERK was clearly detected by
immunofluorescence in YFP-EGFR-ICD Del746-trans-
fected cells. A more intense signal was consistently
obtained with the anti-pAkt antibody, which was there-
fore used in subsequent experiments. As illustrated in Fig-
ure 2C, phosphorylated Akt in YFP-EGFR-ICD Del746-
transfected MCF-7 cells localized preferentially to mem-
brane ruffles and the tip of the lamellipodial protrusions
mentioned above. Remarkably, we did not observe a cor-
relation between the expression levels of ectopic EGFR
ICD and the intensity of the endogenous pAkt signal.
The sensitivity of EGFR mutants to erlotinib can be 
evaluated in the context of YFP-EGFR-ICD
We next evaluated the response of the Del746 mutant in
the context of YFP-EGFR-ICD to the TKI inhibitor erlo-
tinib. The TKI-resistant double mutant Del746/T790M
[24,25] was also tested. Four hours post-transfection, erlo-
tinib at a final concentration ranging from 1 nM to 10 µM
was added to the culture medium, and cells were incu-
bated for 20 hours. Samples were then fixed and immu-
nostained using the anti-pAkt antibody. As illustrated in
Figure 3A, no effect of erlotinib on cells expressing YFP-
EGFR-ICD wt was noted up to 1 µM. At 10 µM, erlotinib
induced the relocation of the chimeric protein to thick
cytoplasmic filaments, reminiscent of actin cables [26].
EGFR can interact with actin [27], and the ICD fragment
used in our assay includes the actin binding domain of
EGFR. However, rhodamine-conjugated phalloidin failed
to show co-localization with YFP-EGFR-ICD filaments
(data not shown), suggesting that they do not contain
actin. In cells expressing YFP-EGFR-ICD Del746, Akt
phosphorylation was detected in both untreated samples
and samples treated with 1 nM erlotinib. However 10 nM
or higher concentration of the drug abrogated Akt phos-
phorylation and induced fibril formation. Surprisingly,
Y1092 phosphorylation of YFP-EGFR-ICD Del746 was
still detected in these fibrils (Figure 3C). In line with pre-
vious observations [25] the T790M mutation abrogated
erlotinib sensitivity. Thus, Akt phosphorylation was read-
ily detected in cells expressing YFP-EGFR-ICD Del746/
T790M, even after treatment with 10 µM erlotinib.
Testing the kinase activity and erlotinib sensitivity of 
uncommon EGFR mutants using the YFP-EGFR-ICD assay
We next applied the YFP-EGFR-ICD-based assay to test
several uncommon EGFR mutations (Figure 4A) on which
limited or no biochemical information is available. These
included exon 20 insertions Ins770SVD and Ins774HV,
and the exon 21 point mutation P848L, which were
detected during our analysis of NSCLC samples (unpub-
lished data). We also tested the exon 21 mutation A859T
identified by other groups [28-30].
These mutations were introduced into YFP-EGFR-ICD and
transient transfection experiments were carried out in
MCF-7 cells. The kinase activity of each mutant (auto-
phosphorylation at Y1092 and phosphorylation of
endogenous Akt), and its response to different concentra-
tions of erlotinib were evaluated as described above.
Other exon 20 and 21 mutations (T790M, S768I and
L858R) that have been previously tested using transfec-
tion-based assays were also included in the assay for com-
parison.
Among the exon 20 mutations tested, Ins770SVD showed
an intermediate level of autophosphorylation, lower than
S768I, but higher than T790M (Figure 4B). It was not pos-
sible to accurately evaluate autophosphorylation of
Ins774HV, since the expression level of this mutant was
consistently low in all attempted experiments. Akt phos-
phorylation was readily detected in cells transfected with
S768I, Ins770SVD or Ins774HV, but not in cells express-
ing T790M (Figure 4B). The phosphorylation of Akt
induced by S768I was abrogated by 100 nM erlotinib, and
fibril formation was noted upon treatment with 1 µM or
higher concentration of the drug. In contrast, the phos-
phorylation of Akt induced by Ins770SVD or Ins774HV
was only abrogated at the highest concentration of erlo-
tinib tested (10 µM). In the case of YFP-EGFR-ICD
Ins770SVD, 10 µM erlotinib also induced relocation of
the chimeric protein to fibrils. No fibrils were observed in
the case of YFP-EGFR-ICD T790M or Ins774HV at any of
the erlotinib concentrations tested.
On the other hand, YFP-EGFR-ICD proteins bearing the
uncommon exon 21 mutation P848L and A859T showed
markedly lower autophosphorylation levels than YFP-
EGFR-ICD L858R (Figure 4C). Neither P848L nor A859T
were able to induce phosphorylation of endogenous Akt.
Erlotinib induced fibrilar relocation of YFP-EGFR-ICD
A859T when applied at 10 µM, but did not have any
apparent effect on P848L at any of the concentrationsPage 5 of 10
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Testing the kinase activity and erlotinib sensitivity of uncommon EGFR mutants using the YFP-EGFR-ICD assayFigure 4
Testing the kinase activity and erlotinib sensitivity of uncommon EGFR mutants using the YFP-EGFR-ICD 
assay. A. Partial amino acid sequence of EGFR exon 20 and exon 21 illustrating the location of the mutations examined (red 
letters). B. Kinase activity and erlotinib sensitivity of different exon 20 mutations. Graph shows that autophosphorylation levels 
are lower for T790M (white diamonds) than for S768I (white squares) or Ins770SVD (black triangles). Low expression levels 
hampered the accurate evaluation of Ins774HV (black circles). Images show that YFP-EGFR T790M did not effectively induce 
phosphorylation of endogenous Akt in MCF-7 cells, and did not relocate into fibrils upon erlotinib treatment. S768I-induced 
pAkt was inhibited by 100 nM erlotinib and the ectopic protein relocated into fibrils at 1 µM. The phosphorylation of Akt 
induced by exon 20 insertions was only inhibited at 10 µM erlotinib. This drug concentration also induced relocation of YFP-
EGFR-ICD Ins770SVD into fibrils. C. Kinase activity and erlotinib sensitivity of different exon 21 mutations. Graph shows that 
the common L858R mutation confers higher autophosphorylation levels to YFP-EGFR-ICD than P848L and A859T. Images 
show that, unlike L858R, these uncommon exon 21 mutants did not induce phosphorylation of endogenous Akt. Erlotinib 
blocked L858R-induced pAkt at 10 nM, and caused relocation of the ectopic protein into fibrils at 100 nM. Both effects were 
readily abrogated by the TKI-resistant mutation T790M. In all cases, data corresponding to one experiment are shown. Each 
EGFR mutant was tested at least twice with similar results.
Molecular Cancer 2007, 6:56 http://www.molecular-cancer.com/content/6/1/56tested. In contrast, YFP-EGFR-ICD L858R induced phos-
phorylation of endogenous Akt, which was inhibited by
10 nM of erlotinib, and 100 nM or higher concentrations
of the drug induced fibril formation. The T790M muta-
tion abrogated the effect of erlotinib on L858R, and the
L858R/T790M double mutant readily induced Akt phos-
phorylation even in the presence of 10 µM erlotinib.
Discussion
In a subset of NSCLC patients, the presence of somatic
mutations in the kinase domain of EGFR may predict the
outcome of treatment with the EGFR TKIs erlotinib and
gefitinib. The favorable clinical response of tumors har-
boring the common exon 19 deletions or the L858R
mutation correlates with the high TKI sensitivity of these
EGFR mutant proteins at the molecular level. However, a
large variety of different EGFR mutant alleles have been
identified in NSCLC patients, and it is becoming increas-
ingly clear that different EGFR mutants may vary dramat-
ically in their sensitivity or resistance to TKIs [15,31-33].
This issue is of particular importance in the context of on-
going prospective clinical studies in which patient selec-
tion is based on the presence of EGFR mutations. In addi-
tion, novel treatment options are being explored for those
NSCLC patients bearing TKI-resistant EGFR mutations.
These options include the use of second-generation irre-
versible EGFR TKIs currently on development, but might
be extended in the future to targeting other components
of the pathway.
Evaluating the biochemical characteristics of mutant
EGFR proteins using in vitro or cell-based assays provides
clues to the phenotypical consequences of each alteration.
Several relatively uncommon EGFR mutants have been
tested in transfection-based assays, using immunoblot
with phosphorylation-specific antibodies to assess EGFR
activity [15,17-21]. In these studies, a homogeneous pop-
ulation of transfected cells was usually generated, by using
viral transduction or by selecting stable transfectants,
which are both labor-intensive and time-consuming pro-
cedures. We describe here a rapid cellular assay system to
evaluate the kinase activity and erlotinib sensitivity of
EGFR mutants, using an YFP-tagged fragment of EGFR
intracellular domain (YFP-EGFR-ICD) and immunofluo-
rescence. Our assay presents several advantageous charac-
teristics with respect to previously used methods. First, by
using a fragment of the receptor lacking the extracellular
domain one would expect to reduce interference from the
experimental context, which may have been partially
responsible for some controversial findings
[4,6,10,19,20]. Furthermore, the use of a shorter EGFR
fragment instead of the full-length receptor renders the
mutagenesis procedure more efficient. Finally, by evaluat-
ing EGFR activity in a single-cell basis, our assay circum-
vents the need of a homogeneous population of
transfected cells allowing the use of transient transfection.
The whole procedure of testing a new EGFR mutant,
including site-directed mutagenesis (2 days), verification
of the construct by sequencing (1 day), transfection,
immunostaining and scoring (3 days) can be completed
in approximately one week. In comparison, the genera-
tion of a population of stably transfected cells would typ-
ically require several weeks of selection in antibiotic-
containing medium.
By using the well-characterized EGFR mutant Del746 as
control, we demonstrate that the YFP-EGFR-ICD-based
assay readily identifies differences between this mutant
and the wild type protein in terms of autophosphoryla-
tion, activation of downstream signaling pathways and
sensitivity to erlotinib. We also show that computer-
assisted measurement of fluorescence intensity can be
used to obtain a semi-quantitative comparison of auto-
phosphorylation levels between different mutants. It must
be acknowledged that immunofluorescence staining is a
less quantitative approach than immunoblot to evaluate
protein phosphorylation levels, a disadvantage that is, in
our view, counterbalanced by the preservation of cellular
morphology. Morphological examination allowed us to
observe that phosphorylated endogenous Akt preferen-
tially localizes to membrane ruffles and the tip of lamel-
lipodial protrusions in cells expressing mutant EGFR-
ICDs. This observation is consistent with the localization
of activated endogenous Akt in growth factor-stimulated
cells and its role in cell motility [[34], and references
therein].
Microscopy analysis led to the unexpected observation
that erlotinib treatment induces the relocation of the YFP-
EGFR-ICD chimeric protein to thick cytoplasmic fila-
ments. Importantly, the wild type protein formed fibrils
only at 10 µM erlotinib, whereas the TKI-sensitive
mutants relocated to fibrils in the presence of 10–100 nM
erlotinib, and this effect was fully abrogated by the erlo-
tinib-resistant T790M mutation. These observations sug-
gest that the relocation of the chimeric YFP-EGFR-ICD
protein into thick fibrils at lower drug concentrations is a
marker of erlotinib sensitivity in our assay. The molecular
basis for this effect of erlotinib is presently unclear. Addi-
tional experiments are required, for example, to clarify
why YFP-EGFR-ICD Del746 remains phosphorylated
(pY1092) in these fibrils in the presence of 500 nM erlo-
tininb, even if downstream signaling (pAkt) is inhibited.
We speculate that erlotinib binding to the ATP-binding
site in the context of YFP-EGFR-ICD molecule may intro-
duce a conformational alteration sufficient to lead to the
aggregation of the chimeric protein. Importantly, we have
noted that such effect is not erlotinib-specific, since a sim-
ilar relocation can be induced by gefitinib treatment (data
not shown). It remains to be further examined if fibril for-Page 7 of 10
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tion. In this case, the YFP-EGFR-ICD assay system could
be adapted for high content screening of potential anti-
EGFR agents, since the shift from a diffuse YFP signal to a
fluorescent signal concentrated in thick fibrils would be
readily detected using automated image analysis. This
possibility is particularly appealing in the context of the
currently on-going effort to develop second-generation
irreversible TKIs and other agents that may circumvent
resistance to TKI associated wit the presence of certain
types of EGFR mutations.
Over the last three years, we have carried out mutational
analysis of EGFR in tumor samples from nearly 300
NSCLC patients [[35,36] and unpublished data]. Several
uncommon EGFR mutants identified in the course of this
analysis were tested using the YFP-EGFR-ICD assay.
Mutations in exon 20, most notably T790M, are usually
associated with resistance to gefitinib and erlotinib
[reviewed in [37]]. We found that Ins770SVD and
Ins774HV are more resistant to erlotinib than S768I in
our assay. These results are in line with previous data
showing increased erlotinib resistance for a similar
(Ins770NPG) mutant [15]. Furthermore, our results show
that both insertions confer higher kinase activity than
T790M, thus underscoring an important difference
between these two types of exon 20 alterations. In this
regard, there has been some controversy regarding the
enhanced kinase activity of T790M-mutant EGFR [22]. We
noted that the autophosphorylation level (pY1092) of
YFP-EGFR-ICD T790M was indeed higher than that of the
wild type protein at lower expression levels (compare
graphs in Figure 1D and Figure 4B), as reported by Vikis et
al [22]. However, the ability of this mutant to activate
downstream signaling was clearly reduced in comparison
to the ICD constructs bearing the Del746, L858R, S768I,
Ins770SVD or Ins774HV mutations. Recent structural
analyses indicate that enhanced activity of EGFR mutants
may derive form the disruption of autoinhibitory interac-
tions that suppress EGFR basal activity [23,38]. Our data
suggest that exon 20 insertions may disrupt these interac-
tions to a greater extent than the T790M point mutation.
On the other hand, our functional analysis indicates that
the uncommon exon 21 mutation P848L is not a kinase-
activating mutation and does not confer increased sensi-
tivity to erlotinib. This change has been detected in both
tumor and normal tissues from NSCLC patients [[39];
Gallegos-Ruiz et al., unpublished data]. Furthermore,
although EGFR and K-ras mutations are in general mutu-
ally exclusive in NSCLC patients [37], a K-Ras mutation
(G12V) was detected in tumor cells bearing the P848L
allele (Gallegos-Ruiz et al., unpublished). Like P848L, the
A859T variant, which has been detected in two non-
responding NSCLC patients [28,29], did not confer
increased kinase activity or erlotinib sensitivity in our test.
Together, the results from the YFP-EGFR-ICD assay and
the clinical behavior of tumors bearing these alterations
suggest that P848L and A859T are likely to be uncommon,
functionally silent EGFR polymorphisms.
Conclusion
In conclusion, we describe here the use of a simple cellular
assay that can be easily implemented to functionally eval-
uate EGFR variants. The ability to rapidly obtain func-
tional information on EGFR variants of unknown
relevance might prove important in the future for the
management of NSCLC patients bearing uncommon
EGFR mutations. In addition, our assay may be used to
determine the response of resistant EGFR mutants to
novel second-generation TKIs or to other therapeutic
agents targeting the EGFR signaling pathway.
Methods
Plasmid construction and site-directed mutagenesis
In order to generate the YFP-EGFR-ICD construct, a DNA
fragment encoding EGFR residues 688–1116 was ampli-
fied by PCR using primers TDG1 and TDG4, and full-
length human EGFR cDNA (kindly provided by Dr. H.
Nakagawa, University of Pennsylvania, Philadelphia) as
template. The amplified product was digested with Hin-
dIII and KpnI and cloned into the pEYFP-C1 mammalian
expression vector (Clontech, Palo Alto, CA). NSCLC- asso-
ciated mutations were subsequently introduced into YFP-
EGFR-ICD using the QuickChange II XL Site-Directed
Mutagenesis Kit (Stratagene, La Jolla, CA) following man-
ufacturer's protocol. In all cases, the sequence of the
inserts was verified by DNA sequence. The sequence of all
primers used is available upon request.
Cell culture, transfection and drug treatment
Human breast cancer cells MCF-7 were grown in Dul-
becco's modified Eagle's medium (BioWhittaker, Walkers-
ville, MD), supplemented with 10% fetal calf serum
(FCS), 100 units/ml penicillin, and 100 µg/ml streptomy-
cin (Gibco-Invitrogen, Breda, The Netherlands). Cells
were seeded onto sterile glass coverslips in twelve-well
trays, and transfected with 0.5–1 µg of plasmid DNA
using the FuGene6 transfection reagent (Roche Molecular
Biochemicals, Almere, The Netherlands), following the
manufacturer's protocol. Erlotinib (Roche Pharmaceuti-
cals, Mannheim, Germany) was added at the indicated
concentration 4 hours after transfection, and the cells
were incubated for 20 hours before being processed for
immunofluorescence analysis. Erlotinib treatment was
always performed in standard culture medium containing
10% FCS.Page 8 of 10
(page number not for citation purposes)
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To evaluate EGFR autophosphorylation, rabbit anti-
pEGFR-Y845 (#2231, diluted 1:180) and mouse anti-
pEGFR-Y1068 (#2236, diluted 1:180) antibodies were
used. Note that the EGFR numbering system used by the
manufacturer (Cell Signaling Technology, Danvers, MA)
does not include the 24-residue signal peptide. According
to the numbering system used in this report, these anti-
bodies recognize residues pY869 and pY1092, respec-
tively. On the other hand, rabbit anti-pAkt-S473 (#9271,
diluted 1:100) and rabbit anti-pERK1/ERK2-T202/Y204
(#9101, diluted 1:100) antibodies, both from Cell Signal-
ing Technology, were used to evaluate activation status of
EGFR downstream pathways.
The immunostaining procedure was as previously
described [40] with minor modifications. Briefly, cells
were fixed using 3.7% formaldehyde in PBS for 30 min-
utes and permeabilized with 0.2% Triton X-100 in PBS for
10 minutes. Following a blocking step with 3% bovine
serum albumin in PBS for 1 hour, the primary antibody
diluted in blocking solution was applied for 1 hour. After
washing with PBS, samples were incubated with Alexa
Fluor 594 (AF-594)-conjugated anti-mouse or anti-rabbit
secondary antibodies (Molecular Probes-Invitrogen,
Breda, The Netherlands) for 45 min. Finally, the cover-
slips were mounted onto microscope slides with Vectash-
ield (Vector, Burlingame, CA). The chromosome stain
Hoechst 33285(Sigma, St Louis, MO) was used to coun-
terstain the cell nuclei.
F-actin staining was carried out by incubating fixed and
permeabilized cells with Rhodamine-conjugated phalloi-
din diluted in blocking solution for 30 minutes (Molecu-
lar Probes-Invitrogen, Breda, The Netherlands).
Slides were examined using an inverted Leica DMIRB/E
fluorescence microscope (Leica Heidelberg, Heidelberg,
Germany). The LeicaQ500MC Quantimet software
V01.01 (Leica Cambridge Ltd., Cambridge, UK) was used
to collect images, keeping exposure time constant to allow
for comparison of signal intensity between different sam-
ples. The same software was used to carry out semi-quan-
titative image analysis of YFP-EGFR-ICD expression level
and pY1092 phosphorylation level. To this end, images
were acquired using 400 × magnification. A cytoplasmic
area was selected (Figure 1D), and the intensity of the flu-
orescent signal within this region was measured in the
green (YFP fluorophore) and the red (AF-594 fluoro-
phore) channels. The intensity of the signal was also
measured in a region outside the cell to determine back-
ground fluorescence. After subtracting the background,
the fluorescence intensity of both fluorophores was plot-
ted against each other using Excel, and the best-fitting
trend line (highest R2 value) was added using the "Add
trend line" feature.
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